BRAF and melanoma: It is noted that the somatic mutation in MAP2K2 was not previously reported in targeted gene panel sequencing of PDTC9,11–13.The MAP2K2 mutation is related to a high resistance in MEK inhibitors in melanomas with a BRAF mutation35, and MAP2K2 upregulation is known to induce the progress of clear cell renal carcinoma36.